vs
Digimarc CORP（DMRC）与Alpha Teknova, Inc.（TKNO）财务数据对比。点击上方公司名可切换其他公司
Alpha Teknova, Inc.的季度营收约是Digimarc CORP的1.1倍（$10.0M vs $8.9M），Digimarc CORP净利率更高（-47.2% vs -47.7%，领先0.4%），Alpha Teknova, Inc.同比增速更快（7.8% vs 2.9%），Digimarc CORP自由现金流更多（$895.0K vs $-810.0K），过去两年Alpha Teknova, Inc.的营收复合增速更高（3.7% vs -5.3%）
迪吉马克公司是一家企业软件与服务提供商，其主打产品包含带数字标识符的软件，主要用于解决防伪问题、验证产品真伪、提升回收准确性以及实现供应链可追溯，产品可广泛应用于服装、快消品、美妆健康、汽车等多个行业领域。
Alpha Teknova, Inc.是一家生命科学企业，研发并生产专用试剂、细胞培养基及定制实验室解决方案，服务生物制药、分子诊断及学术研究领域客户，主要面向北美市场，为药物研发、诊断测试及生命科学研究流程提供支持。
DMRC vs TKNO — 直观对比
营收规模更大
TKNO
是对方的1.1倍
$8.9M
营收增速更快
TKNO
高出4.9%
2.9%
净利率更高
DMRC
高出0.4%
-47.7%
自由现金流更多
DMRC
多$1.7M
$-810.0K
两年增速更快
TKNO
近两年复合增速
-5.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.9M | $10.0M |
| 净利润 | $-4.2M | $-4.8M |
| 毛利率 | 63.5% | 32.5% |
| 营业利润率 | -48.2% | -46.2% |
| 净利率 | -47.2% | -47.7% |
| 营收同比 | 2.9% | 7.8% |
| 净利润同比 | 51.4% | 16.8% |
| 每股收益（稀释后） | $-0.18 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DMRCTKNO
| Q4 25 | $8.9M | $10.0M | ||
| Q3 25 | $7.6M | $10.5M | ||
| Q2 25 | $8.0M | $10.3M | ||
| Q1 25 | $9.4M | $9.8M | ||
| Q4 24 | $8.7M | $9.3M | ||
| Q3 24 | $9.4M | $9.6M | ||
| Q2 24 | $10.4M | $9.6M | ||
| Q1 24 | $9.9M | $9.3M |
净利润DMRCTKNO
| Q4 25 | $-4.2M | $-4.8M | ||
| Q3 25 | $-8.2M | $-4.3M | ||
| Q2 25 | $-8.2M | $-3.6M | ||
| Q1 25 | $-11.7M | $-4.6M | ||
| Q4 24 | $-8.6M | $-5.7M | ||
| Q3 24 | $-10.8M | $-7.6M | ||
| Q2 24 | $-9.3M | $-5.4M | ||
| Q1 24 | $-10.3M | $-8.1M |
毛利率DMRCTKNO
| Q4 25 | 63.5% | 32.5% | ||
| Q3 25 | 58.3% | 30.7% | ||
| Q2 25 | 58.8% | 38.7% | ||
| Q1 25 | 65.0% | 30.7% | ||
| Q4 24 | 60.8% | 23.0% | ||
| Q3 24 | 62.4% | 0.9% | ||
| Q2 24 | 66.1% | 29.2% | ||
| Q1 24 | 62.5% | 23.8% |
营业利润率DMRCTKNO
| Q4 25 | -48.2% | -46.2% | ||
| Q3 25 | -109.7% | -38.4% | ||
| Q2 25 | -105.2% | -32.9% | ||
| Q1 25 | -128.9% | -50.7% | ||
| Q4 24 | -105.1% | -60.7% | ||
| Q3 24 | -120.4% | -77.6% | ||
| Q2 24 | -96.2% | -53.0% | ||
| Q1 24 | -109.2% | -86.0% |
净利率DMRCTKNO
| Q4 25 | -47.2% | -47.7% | ||
| Q3 25 | -106.9% | -41.0% | ||
| Q2 25 | -102.6% | -34.7% | ||
| Q1 25 | -125.2% | -47.4% | ||
| Q4 24 | -99.9% | -61.7% | ||
| Q3 24 | -113.9% | -79.0% | ||
| Q2 24 | -89.3% | -55.8% | ||
| Q1 24 | -104.0% | -87.2% |
每股收益（稀释后）DMRCTKNO
| Q4 25 | $-0.18 | $-0.08 | ||
| Q3 25 | $-0.38 | $-0.08 | ||
| Q2 25 | $-0.38 | $-0.07 | ||
| Q1 25 | $-0.55 | $-0.09 | ||
| Q4 24 | $-0.40 | $-0.09 | ||
| Q3 24 | $-0.50 | $-0.15 | ||
| Q2 24 | $-0.43 | $-0.13 | ||
| Q1 24 | $-0.50 | $-0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.9M | $21.3M |
| 总债务越低越好 | — | $13.1M |
| 股东权益账面价值 | $40.2M | $68.8M |
| 总资产 | $53.0M | $103.6M |
| 负债/权益比越低杠杆越低 | — | 0.19× |
8季度趋势，按日历期对齐
现金及短期投资DMRCTKNO
| Q4 25 | $12.9M | $21.3M | ||
| Q3 25 | $12.6M | $22.1M | ||
| Q2 25 | $16.1M | $24.0M | ||
| Q1 25 | $21.6M | $26.3M | ||
| Q4 24 | $28.7M | $30.4M | ||
| Q3 24 | $33.7M | $31.7M | ||
| Q2 24 | $41.5M | $18.6M | ||
| Q1 24 | $48.9M | $21.6M |
总债务DMRCTKNO
| Q4 25 | — | $13.1M | ||
| Q3 25 | — | $13.1M | ||
| Q2 25 | — | $13.0M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | — | $9.4M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | — | $12.3M | ||
| Q1 24 | — | $13.2M |
股东权益DMRCTKNO
| Q4 25 | $40.2M | $68.8M | ||
| Q3 25 | $41.4M | $72.7M | ||
| Q2 25 | $46.5M | $76.1M | ||
| Q1 25 | $50.0M | $78.6M | ||
| Q4 24 | $61.4M | $82.4M | ||
| Q3 24 | $70.2M | $87.3M | ||
| Q2 24 | $77.2M | $78.9M | ||
| Q1 24 | $84.5M | $83.4M |
总资产DMRCTKNO
| Q4 25 | $53.0M | $103.6M | ||
| Q3 25 | $55.4M | $107.6M | ||
| Q2 25 | $60.7M | $110.5M | ||
| Q1 25 | $66.5M | $114.0M | ||
| Q4 24 | $75.8M | $118.8M | ||
| Q3 24 | $85.0M | $124.1M | ||
| Q2 24 | $93.4M | $115.4M | ||
| Q1 24 | $99.7M | $120.8M |
负债/权益比DMRCTKNO
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | 0.18× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $991.0K | $-462.0K |
| 自由现金流经营现金流 - 资本支出 | $895.0K | $-810.0K |
| 自由现金流率自由现金流/营收 | 10.0% | -8.1% |
| 资本支出强度资本支出/营收 | 1.1% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-12.3M | $-9.8M |
8季度趋势，按日历期对齐
经营现金流DMRCTKNO
| Q4 25 | $991.0K | $-462.0K | ||
| Q3 25 | $-2.6M | $-2.0M | ||
| Q2 25 | $-4.7M | $-2.1M | ||
| Q1 25 | $-5.5M | $-4.1M | ||
| Q4 24 | $-4.2M | $-936.0K | ||
| Q3 24 | $-7.1M | $-2.1M | ||
| Q2 24 | $-6.8M | $-2.8M | ||
| Q1 24 | $-8.4M | $-6.6M |
自由现金流DMRCTKNO
| Q4 25 | $895.0K | $-810.0K | ||
| Q3 25 | $-2.8M | $-2.4M | ||
| Q2 25 | $-4.9M | $-2.3M | ||
| Q1 25 | $-5.5M | $-4.3M | ||
| Q4 24 | $-4.2M | $-1.5M | ||
| Q3 24 | $-7.2M | $-2.4M | ||
| Q2 24 | $-6.9M | $-3.0M | ||
| Q1 24 | $-8.5M | $-6.7M |
自由现金流率DMRCTKNO
| Q4 25 | 10.0% | -8.1% | ||
| Q3 25 | -36.9% | -22.6% | ||
| Q2 25 | -61.0% | -22.4% | ||
| Q1 25 | -59.1% | -44.0% | ||
| Q4 24 | -49.1% | -16.2% | ||
| Q3 24 | -75.7% | -25.0% | ||
| Q2 24 | -66.1% | -30.7% | ||
| Q1 24 | -85.8% | -71.8% |
资本支出强度DMRCTKNO
| Q4 25 | 1.1% | 3.5% | ||
| Q3 25 | 2.9% | 3.7% | ||
| Q2 25 | 2.5% | 2.0% | ||
| Q1 25 | 0.6% | 2.1% | ||
| Q4 24 | 0.2% | 6.1% | ||
| Q3 24 | 0.7% | 3.5% | ||
| Q2 24 | 0.3% | 1.2% | ||
| Q1 24 | 1.1% | 1.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DMRC
| Subscription | $5.3M | 60% |
| The Government | $3.6M | 41% |
TKNO
| Lab Essentials | $6.8M | 68% |
| Clinical Solutions | $2.7M | 27% |
| Other | $435.0K | 4% |
